New treatments for denervating diseases

Journal of Child Neurology

Volumn 20, Issue 3, 2005, Pages 258-262

  Pleasure, David ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ARYLBUTYRIC ACID DERIVATIVE; ASCORBIC ACID; BUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; PERIPHERAL MYELIN PROTEIN 22; PHOSPHODIESTERASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SILENT INFORMATION REGULATOR PROTEIN 2; SUPEROXIDE DISMUTASE; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DRUG EFFICACY; ENZYME ACTIVITY; FABRY DISEASE; GENE DELETION; GENE DUPLICATION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; KENNEDY DISEASE; MOTOR NEURON DISEASE; MOUSE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION;

EID: 17644381943     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738050200031101     Document Type: Article

References (70)

1. Thurberg BL, Byers HR, Granter SR, et al: Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-908.
2. Desnick RJ, Brady R, Barranger J, et al: Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346.
3. Mehta A, Ricci R, Widmer U, et al: Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-244.
4. Linthorst GE, Hollak CE, Donker-Koopman WE, et al: Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-1595.
5. Park J, Murray GJ, Limaye A, et al: Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA 2003;100:3450-3454.
6. Ziegler RJ, Lonning SM, Armentano D, et al: AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther 2003;9:231-240.
7. Frustaci A, Chimenti C, Ricci R, et al: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
8. Fan JQ, Ishii S, Asano N, Suzuki Y: Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-115.
9. Kolter T, Wendeler M: Chemical chaperones - A new concept in drug research. Chembiochemistry 2003;4:260-264.
10. Ishii S, Yoshioka H, Mannen K, et al: Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: A biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta 2004;1690:250-257.
11. Fidzianska A, Rafalowska J: Motoneuron death in normal and spinal muscular atrophy-affected human fetuses. Acta Neuropathol (Berl) 2002;104:363-368.
12. Chung BH, Wong VC, Ip P: Spinal muscular atrophy: Survival pattern and functional status. Pediatrics 2004;114:e548-e553.
13. Parsons DW, McAndrew PE, Iannaccone ST, et al: Intragenic telSMN mutations: Frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet 1998;63:1712-1723.
14. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G: A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998;95:615-624.
15. Wang J, Dreyfuss G: A cell system with targeted disruption of the SMN gene. J Biol Chem 2001;276:9599-9605.
16. Campbell L, Potter A, Ignatius J, et al: Genomic variation and gene conversion in spinal muscular atrophy: Implications for disease process and clinical phenotype. Am J Hum Genet 1997;61:40-50.
17. MacLeod MJ, Taylor JE, Lunt PW, et al: Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol 1999;3:65-72.
18. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ: Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet 2004;130A:307-310.
19. Andreassi C, Angelozzi C, Tiziano FD, et al: Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004;12:59-65.
20. Mercuri E, Bertini E, Messina S, et al: Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004; 14:130-135.
21. Sumner CJ, Huynh TN, Markowitz JA, et al: Valproic acid increases SMN levels in spinal muscular atorphy patient cells. Ann Neurol 2003;54:647-654.
22. Lupski JR, Chance PF, Garcia CA: Inherited primary peripheral neuropathies. Molecular genetics and clinical implications. JAMA 1993;270:2326-2330.
23. Kiyosawa H, Lensch MW, Chance PF: Analysis of the CMT1A-REP repeat: Mapping crossover breakpoints in CMT1A and HNPP. Hum Mol Genet 1995;4:2327-2334.
24. Zoidl G, Blass-Kampmann S, D'Urso D, et al: Retroviral-mediated gene transfer of the peripheral myelin protein PMP22 in Schwann cells: Modulation of cell growth. EMBO J 1995;14:1122-1128.
25. Robaglia-Schlupp A, Pizant J, Norreel JC, et al: PMP22 overexpression causes dysmyelination in mice. Brain 2002;125:2213-2221.
26. Sobue G, Pleasure D: Schwann cell galactocerebroside induced by derivatives of adenosine-3′,5′-monophosphate. Science 1984;224:72-74.
27. Lemke G, Chao M: Axons regulate Schwann cell expression of the major myelin and NGF receptor genes. Development 1988; 102:499-504.
28. Saberan-Djoneidi D, Sanguedolce V, Assouline Z, et al: Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 2000;248:223-231.
29. Suter U, Snipes GJ, Schoener-Scott R, et al: Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 1994;269:25795-25808.
30. Passage E, Norreel JC, Noack-Fraissignes P, et al: Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401.
31. Lieberman AP, Fischbeck KH: Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000;23:843-850.
32. Mariotti C, Castellotti B, Pareyson D, et al: Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: A clinical and molecular study of 30 families. Neuromuscul Disord 2000; 10:391-397.
33. Adachi H, Katsuno M, Minamiyama M, et al: Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 2003;23:2203-2211.
34. Minamiyama M, Katsuno M, Adachi H et al: Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004;13:1183-1192.
35. Schaffer G, Breuer P, Boteva R, et al: Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol Cell 2004;15:95-105.
36. Sopher BL, Thomas PS Jr, LaFebre-Bernt MA, et al: Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004;41:687-699.
37. Katsuno M, Sobue G: Polyglutamine diminishes VEGF; passage to motor neuron death? Neuron 2004;41:677-679.
38. van Den Bosch L, Storkebaum E, Vleminckx V, et al: Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol Dis 2004;17:21-28.
39. Hobson MI, Green CJ, Terenghi G: VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat 2000;197:591-605.
40. Schratzberger P, Walter DH, Rittig K, et al: Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-1092.
41. Rosenstein JM, Krum JM: New roles for VEGF in nervous tissue - Beyond blood vessels. Exp Neurol 2004;187:246-253.
42. Oosthuyse B, Moons L, Storkebaum E, et al: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;128:131-138.
43. Liu J, Lillo C, Jonsson PA, et al: Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria Neuron 2004;43:5-17.
44. Murakami T, Ilieva H, Shiote M, et al: Hypoxic induction of vascular endothelial growth factor is selectively impaired in mice carrying the mutant SOD1 gene. Brain Res 2003;989:231-237.
45. Azzouz M, Ralph GS, Storkebaum E, et al: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413-417.
46. Zheng C, Nennesmo I, Fadeel B, Henter JI: Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004;56:564-567.
47. Storkebaum E, Lambrechts D, Dewerchin M, et al: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92.
48. Devos D, Moreau C, Lassalle P, et al: Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127-2129.
49. Lambrechts D, Storkebaum E, Morimoto M, et al: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.
50. Cleveland JL: A new piece of the ALS puzzle. Nat Genet 2003;34:357-358.
51. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
52. Plante-Bordeneuve V, Said G: Dejerine-Sottas disease and hereditary demyelinating polyneuropathy of infancy. Muscle Nerve 2002;26:608-621.
53. Bhatt DH, Otto SJ, Depoister B, Fetcho JR: Cyclic AMP-induced repair of zebrafish spinal circuits. Science 2004;305:254-258.
54. Nikulina E, Tidwell JL, Dai HN, et al: The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A 2004;101:8786-8790.
55. Harper JM, Krishnan C, Darman JS, et al: Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A 2004;101:7123-7128.
56. Bisby MA, Chen S: Delayed wallerian degeneration in sciatic nerves of C57BL/Ola mice is associated with impaired regeneration of sensory axons. Brain Res 1990;530:117-120.
57. Brown MC, Booth CM, Lunn ER, Perry VH: Delayed response to denervation in muscles of C57BL/Ola mice. Neuroscience 1991;43:279-283.
58. s mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol 2002;52:442-447.
59. Ferri A, Sanes JR, Coleman MP, et al: Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol 2003;13:669-673.
60. s mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 2003;23:2833-2839.
61. s) mouse. Proc Natl Acad Sci U S A 2000;97: 11377-11382.
62. Mack TGA, Reiner M, Beirowski B, et al: Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001;4:1199-1206.
63. Mi W, Glass JD, Coleman MP: Stable inheritance of an 85-kb triplication in C57BL/WldS mice. Mutat Res 2003;526:33-37.
64. Araki T, Sasaki Y, Milbrandt J: Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-1013.
65. Bedalov A, Simon JA: NAD to the rescue. Science 2004;305:954-955.
66. Cohen HY, Miller C, Bitterman KJ, et al: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-392.
67. Rogina B, Helfand SL: Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 2004;101:15998-16003.
68. Obrosova IG, Li F, Abatan OI, et al: Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004;53:711-720.
69. Li F, Szabo C, Pacher P, et al: Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 2004; 47:710-717.
70. Lin S-J, Ford E, Haigis M, et al: Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004;18:12-16.